新辅助化疗对乳腺癌ER PR HER-2及Ki-67表达影响的研究进展

Research progress on impact of neoadjuvant chemotherapy on the expression of ER, PR, HER-2, and Ki-67 in breast cancer

摘要: 目前乳腺癌已成为女性发病率最高的恶性肿瘤，新辅助化疗（neoadjuvant chemotherapy，NAC）后雌激素受体（estrogen receptor，ER）、孕激素受体（progesterone receptor，PR）和人表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）、Ki-67表达情况会有不同程度变化，这种变化机制是否会影响后续治疗方案的选择尚无定论。本文将就NAC对乳腺癌ER、PR、HER-2及Ki-67表达影响的研究进展进行综述。

Abstract: Breast cancer has the highest incidence rate among all malignancies in women. The expression of estrogen receptors (ERs), progesterone receptors (PRs), human epidermal growth factor receptor-2 (HER-2), and Ki-67 changes to varying degrees after neoadjuvant chemotherapy. Whether the mechanism underlying these changes will affect the choice of subsequent treatment options remains unknown. We summarize the research progress of neoadjuvant chemotherapy on the expression of ER, PR, HER-2 and Ki-67 in breast cancer.